Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in the U.S.: $34M in Q3 2026, down 61.4% from a year earlier.
Latest, Q3 2026
34
Period ended Sep 30, 2026
Change on a year earlier
-61.4%
88 in Q3 2025
History
32 quarters
Since Q4 2018
Sources
32
Documents cited below
Where the Q3 2026 figure comes from
“|| Promacta/Revolade | Established brands | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) | 34 | – 61 | 108 | – 61 | – 61 | 142 | – 61 | – 61”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up net Sales in the U.S.
Cite this data
StockData. (2026). Novartis Net Sales in the U.S. ($M), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-promacta-revolade-us-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.